Qube Research & Technologies Ltd Buys Shares of 639 Chemed Co. (NYSE:CHE)

Qube Research & Technologies Ltd bought a new stake in shares of Chemed Co. (NYSE:CHE) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 639 shares of the company’s stock, valued at approximately $231,000.

A number of other large investors also recently made changes to their positions in the business. TimesSquare Capital Management LLC acquired a new stake in shares of Chemed during the first quarter worth $54,316,000. AJO LP boosted its holdings in shares of Chemed by 141.7% during the first quarter. AJO LP now owns 145,216 shares of the company’s stock worth $46,479,000 after purchasing an additional 85,132 shares during the last quarter. Ellis Investment Partners LLC acquired a new stake in shares of Chemed during the first quarter worth $70,000. FMR LLC boosted its holdings in shares of Chemed by 27.0% during the first quarter. FMR LLC now owns 311,951 shares of the company’s stock worth $99,847,000 after purchasing an additional 66,276 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Chemed by 489.0% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 66,391 shares of the company’s stock worth $21,250,000 after purchasing an additional 55,120 shares during the last quarter. Hedge funds and other institutional investors own 87.14% of the company’s stock.

Shares of CHE opened at $435.69 on Thursday. The company has a current ratio of 0.81, a quick ratio of 0.78 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $6.90 billion, a P/E ratio of 36.52, a price-to-earnings-growth ratio of 2.95 and a beta of 1.14. The stock’s fifty day simple moving average is $396.70 and its 200 day simple moving average is $345.80. Chemed Co. has a twelve month low of $260.03 and a twelve month high of $441.48.

Chemed (NYSE:CHE) last issued its earnings results on Thursday, July 25th. The company reported $3.36 earnings per share for the quarter, topping the consensus estimate of $3.09 by $0.27. The business had revenue of $473.60 million for the quarter, compared to analyst estimates of $471.72 million. Chemed had a return on equity of 35.63% and a net margin of 10.94%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the company posted $2.81 EPS. Sell-side analysts predict that Chemed Co. will post 13.54 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Monday, August 12th will be given a $0.32 dividend. This is a positive change from Chemed’s previous quarterly dividend of $0.30. This represents a $1.28 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, August 9th. Chemed’s dividend payout ratio (DPR) is 10.73%.

Several equities research analysts have recently issued reports on CHE shares. Royal Bank of Canada raised their price objective on Chemed to $405.00 and gave the stock a “sector perform” rating in a report on Monday, July 29th. Zacks Investment Research cut Chemed from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. ValuEngine upgraded Chemed from a “hold” rating to a “buy” rating in a report on Friday, June 7th. Finally, Oppenheimer raised their price objective on Chemed from $400.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $383.75.

In related news, Director Donald E. Saunders sold 400 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $432.87, for a total value of $173,148.00. Following the transaction, the director now directly owns 7,408 shares of the company’s stock, valued at approximately $3,206,700.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George J. Walsh III bought 500 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was purchased at an average cost of $412.86 per share, for a total transaction of $206,430.00. Following the completion of the transaction, the director now directly owns 4,520 shares in the company, valued at approximately $1,866,127.20. The disclosure for this purchase can be found here. Insiders sold a total of 38,902 shares of company stock worth $16,589,364 over the last ninety days. Corporate insiders own 3.96% of the company’s stock.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.

Featured Story: Why do corrections happen?

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.